Proteasome Inhibitors: An Expanding Army Attacking a

Chemistry and Biology

19, 99-115

DOI: 10.1016/j.chembiol.2012.01.003

Citation Report

#	Article	IF	Citations
1	Unassembled CD147 is an endogenous endoplasmic reticulumâ€“associated degradation substrate. Molecular Biology of the Cell, 2012, 23, 4668-4678.	0.9	78
2	Development of proteasome inhibitors as research tools and cancer drugs. Journal of Cell Biology, 2012, 199, 583-588.	2.3	232
3	Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. OncoTargets and Therapy, 2012, 5, 237.	1.0	23
4	p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance. Frontiers in Oncology, 2012, 2, 173.	1.3	37
5	Peptido Sulfonyl Fluorides as New Powerful Proteasome Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 10995-11003.	2.9	67
6	Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance. Journal of Medicinal Chemistry, 2012, 55, 10317-10327.	2.9	80
7	Mitosis-Targeting Natural Products for Cancer Prevention and Therapy. Current Drug Targets, 2012, 13, 1820-1830.	1.0	33
9	Inhibitors for the Immunoâ€•and Constitutive Proteasome: Current and Future Trends in Drug Development. Angewandte Chemie - International Edition, 2012, 51, 8708-8720.	7.2	160
10	The Carmaphycins: New Proteasome Inhibitors Exhibiting an Î±,Î²â€Epoxyketone Warhead from a Marine Cyanobacterium. ChemBioChem, 2012, 13, 810-817.	1.3	98
11	Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer. Molecular Biology Reports, 2013, 40, 2019-2034.	1.0	25
12	Drug Allergy. , 2013, , .		31
14	Targeting the ubiquitinâ€“proteasome system for cancer therapy. Expert Opinion on Therapeutic Targets, 2013, 17, 1091-1108.	1.5	157
15	Investigation of the Noncovalent Binding Mode of Covalent Proteasome Inhibitors around the Transition State by Combined Use of Cyclopropylic Strain-Based Conformational Restriction and Computational Modeling. Journal of Medicinal Chemistry, 2013, 56, 5829-5842.	2.9	24
16	The RNA exosome and proteasome: common principles of degradation control. Nature Reviews Molecular Cell Biology, 2013, 14, 654-660.	16.1	74
17	Targeting the unfolded protein response in disease. Nature Reviews Drug Discovery, 2013, 12, 703-719.	21.5	765
18	C1 and N5 derivatives of cerpegin: Synthesis of a new series based on structureâ€“activity relationships to optimize their inhibitory effect on 20S proteasome. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2696-2703.	1.0	11
19	ROS inhibitor N-acetyl-<scp>L</scp>-cysteine antagonizes the activity of proteasome inhibitors. Biochemical Journal, 2013, 454, 201-208.	1.7	274
20	Quantum Mechanics-Based Scoring Rationalizes the Irreversible Inactivation of Parasitic Schistosoma mansoni Cysteine Peptidase by Vinyl Sulfone Inhibitors. Journal of Physical Chemistry B, 2013, 117, 14973-14982.	1.2	43

#	Article	IF	Citations
21	Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?. Critical Reviews in Oncology/Hematology, 2013, 85, 363-372.	2.0	61
22	Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6886-6889.	1.0	26
23	Î±- and Î²-hydrazino acid-based pseudopeptides inhibit the chymotrypsin-like activity of the eukaryotic 20S proteasome. European Journal of Medicinal Chemistry, 2013, 70, 505-524.	2.6	19
24	Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer and Metastasis Reviews, 2013, 32, 723-761.	2.7	52
25	Pharmaceutical agents from filamentous marine cyanobacteria. Drug Discovery Today, 2013, 18, 863-871.	3.2	45
26	Novel oleanolic vinyl boronates: Synthesis and antitumor activity. European Journal of Medicinal Chemistry, 2013, 63, 46-56.	2.6	19
27	A role for paralog-specific sumoylation in histone deacetylase 1 stability. Journal of Molecular Cell Biology, 2013, 5, 416-427.	1.5	38
28	Design and synthesis of the stabilized analogs of belactosin A with the unnatural cis-cyclopropane structure. Organic and Biomolecular Chemistry, 2013, 11, 6615.	1.5	16
29	C-terminal trans,trans-muconic acid ethyl ester partial retro-inverso pseudopeptides as proteasome inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 1034-1039.	2.5	4
30	Noncompetitive Modulation of the Proteasome by Imidazoline Scaffolds Overcomes Bortezomib Resistance and Delays MM Tumor Growth in Vivo. ACS Chemical Biology, 2013, 8, 578-587.	1.6	29
31	P97/CDC-48: Proteostasis control in tumor cell biology. Cancer Letters, 2013, 337, 26-34.	3.2	55
32	Targeting the NF-ÎºB Pathway in Cancer Therapy. Surgical Oncology Clinics of North America, 2013, 22, 705-746.	0.6	91
33	Improving Carbeneâ€“Copper-Catalyzed Asymmetric Synthesis of Î±-Aminoboronic Esters Using Benzimidazole-Based Precursors. Journal of Organic Chemistry, 2013, 78, 3405-3409.	1.7	43
34	Synthesis and Pharmacology of Proteasome Inhibitors. Angewandte Chemie - International Edition, 2013, 52, 5450-5488.	7.2	82
35	Conformational Dynamics of the Rpt6 ATPase in Proteasome Assembly and Rpn14 Binding. Structure, 2013, 21, 753-765.	1.6	21
36	Proteasome Regulation by ADP-Ribosylation. Cell, 2013, 153, 614-627.	13.5	126
37	Proteasome Inhibition as a Novel Strategy for Cancer Treatment. , 2013, , 303-329.		2
38	Recent advances in proteasome inhibitor discovery. Expert Opinion on Drug Discovery, 2013, 8, 537-568.	2.5	12

#	Article	IF	Citations
39	Targeting FOXM1 in cancer. Biochemical Pharmacology, 2013, 85, 644-652.	2.0	144
40	Proteasome inhibitors in acute leukemia. Expert Review of Anticancer Therapy, 2013, 13, 327-337.	1.1	38
41	Proteomics Guided Discovery of Flavopeptins: Anti-proliferative Aldehydes Synthesized by a Reductase Domain-Containing Non-ribosomal Peptide Synthetase. Journal of the American Chemical Society, 2013, 135, 10449-10456.	6.6	28
43	Inhibition of the Human Proteasome by Imidazoline Scaffolds. Journal of Medicinal Chemistry, 2013, 56, 5974-5978.	2.9	36
44	Manipulation of Host Proteasomes as a Virulence Mechanism of Plant Pathogens. Annual Review of Phytopathology, 2013, 51, 521-542.	3.5	36
45	Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65. Journal of Biomedical Science, 2013, 20, 13.	2.6	29
46	Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Experimental Hematology and Oncology, 2013, 2, 2.	2.0	17
47	Regulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservation. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H267-H278.	1.5	16
48	Drugs Used for Chemotherapy. , 2013, , 399-418.		1
49	Deubiquitinases Regulate the Activity of Caspase-1 and Interleukin-1Î² Secretion via Assembly of the Inflammasome. Journal of Biological Chemistry, 2013, 288, 2721-2733.	1.6	154
50	Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model. Molecular Cancer Therapeutics, 2013, 12, 1140-1150.	1.9	68
51	In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome. Molecular Cancer Therapeutics, 2013, 12, 2494-2504.	1.9	22
52	Identification of a Molecular Target of a Novel Fungal Metabolite, Pyrrolizilactone, by Phenotypic Profiling Systems. ChemBioChem, 2013, 14, 2456-2463.	1.3	26
53	Deubiquitinase Inhibition of 19S Regulatory Particles by 4-Arylidene Curcumin Analog AC17 Causes NF-ÎºB Inhibition and p53 Reactivation in Human Lung Cancer Cells. Molecular Cancer Therapeutics, 2013, 12, 1381-1392.	1.9	57
55	The Protective Effects of the Proteasome Inhibitor Bortezomib (Velcade) on Ischemia-Reperfusion Injury in the Rat Retina. PLoS ONE, 2013, 8, e64262.	1.1	26
56	Non-Covalent Proteasome Inhibitors. Current Pharmaceutical Design, 2013, 19, 4115-4130.	0.9	18
57	Proteasomes and Proteasomal Gene Polymorphism in Association with Inflammation and Various Diseases. Medicina (Lithuania), 2013, 49, 33.	0.8	8
58	Gold(III)-Dithiocarbamato Peptidomimetics in the Forefront of the Targeted Anticancer Therapy: Preclinical Studies against Human Breast Neoplasia. PLoS ONE, 2014, 9, e84248.	1.1	42

#	Article	IF	Citations
59	Effects of an Anticarcinogenic Bowman-Birk Protease Inhibitor on Purified 20S Proteasome and MCF-7 Breast Cancer Cells. PLoS ONE, 2014, 9, e86600.	1.1	42
60	Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy. Current Medicinal Chemistry, 2014, 22, 264-289.	1.2	178
61	Sensitive detection of proteasomal activation using the Deg-On mammalian synthetic gene circuit. Nature Communications, 2014, 5, 3612.	5.8	24
62	Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy. Frontiers in Physiology, 2014, 5, 484.	1.3	24
63	1-Hydroxyethylhalenaquinone: A New Proteasome Inhibitor from the Marine Sponge Xestospongia sp.. Heterocycles, 2014, 89, 2605.	0.4	11
64	Integrative Quantitative Proteomics Unveils Proteostasis Imbalance in Human Hepatocellular Carcinoma Developed on Nonfibrotic Livers. Molecular and Cellular Proteomics, 2014, 13, 3473-3483.	2.5	15
65	Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response. ACS Medicinal Chemistry Letters, 2014, 5, 1278-1283.	1.3	19
66	¹⁹F NMR monitoring of the eukaryotic 20S proteasome chymotrypsin-like activity: an investigative tool for studying allosteric regulation. Organic and Biomolecular Chemistry, 2014, 12, 4576-4581.	1.5	14
67	Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome. Journal of Peptide Science, 2014, 20, 649-656.	0.8	10
68	Toward Understanding Induction of Oxidative Stress and Apoptosis by Proteasome Inhibitors. Antioxidants and Redox Signaling, 2014, 21, 2419-2443.	2.5	24
69	Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations. Journal of Molecular Modeling, 2014, 20, 2515.	0.8	15
70	Proteasome Inhibitors with Photocontrolled Activity. ChemBioChem, 2014, 15, 2053-2057.	1.3	59
71	Computational Inhibition Studies of the Human Proteasome by Argyrinâ€Based Analogues with Subunit Specificity. Chemical Biology and Drug Design, 2014, 84, 99-107.	1.5	9
72	Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. Journal of Inflammation, 2014, 11, 23.	1.5	96
73	The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma. Leukemia and Lymphoma, 2014, 55, 1707-1714.	0.6	26
74	Inhibitory Effect of b-AP15 on the 20S Proteasome. Biomolecules, 2014, 4, 931-939.	1.8	1
75	Goldâ€Catalyzed Intermolecular Cï£¿S Bond Formation: Efficient Synthesis of Î±â€Substituted Vinyl Sulfones. Angewandte Chemie - International Edition, 2014, 53, 4657-4661.	7.2	124
76	Baceridin, a Cyclic Hexapeptide from an Epiphytic Bacillus Strain, Inhibits the Proteasome. ChemBioChem, 2014, 15, 1021-1029.	1.3	22

#	Article	IF	Citations
77	Peptideâ€Based Proteasome Inhibitors in Anticancer Drug Design. Medicinal Research Reviews, 2014, 34, 1001-1069.	5.0	46
78	Neurotrophic Natural Products: Chemistry and Biology. Angewandte Chemie - International Edition, 2014, 53, 956-987.	7.2	106
79	Paradigms of protein degradation by the proteasome. Current Opinion in Structural Biology, 2014, 24, 156-164.	2.6	102
80	Discovery of PI-1840, a Novel Noncovalent and Rapidly Reversible Proteasome Inhibitor with Anti-tumor Activity. Journal of Biological Chemistry, 2014, 289, 11906-11915.	1.6	20
81	New C4- and C1-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: Evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1571-1580.	1.0	15
82	Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones. Bioorganic and Medicinal Chemistry, 2014, 22, 3091-3095.	1.4	6
83	Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts. Future Medicinal Chemistry, 2014, 6, 1249-1263.	1.1	15
84	Noncovalent Fluorescent Probes of Human Immuno- and Constitutive Proteasomes. Journal of Medicinal Chemistry, 2014, 57, 9211-9217.	2.9	5
85	Optimised synthesis of diamino-triazinylmethyl benzoates as inhibitors of Rad6B ubiquitin conjugating enzyme. Tetrahedron Letters, 2014, 55, 7015-7018.	0.7	8
86	Targeting the Ubiquitin-Proteasome System in Atherosclerosis: Status Quo, Challenges, and Perspectives. Antioxidants and Redox Signaling, 2014, 21, 2344-2363.	2.5	29
87	Asymmetric synthesis of stable Î±-aminoboronic esters catalyzed by N-heterocylic carbene and copper(i) chloride. RSC Advances, 2014, 4, 21131.	1.7	15
88	Proteasome inhibitors â€“ molecular basis and current perspectives in multiple myeloma. Journal of Cellular and Molecular Medicine, 2014, 18, 947-961.	1.6	144
89	Proteasome inhibitor patents (2010 â€“ present). Expert Opinion on Therapeutic Patents, 2014, 24, 369-382.	2.4	4
90	Pharmacophore modeling technique applied for the discovery of proteasome inhibitors. Expert Opinion on Drug Discovery, 2014, 9, 931-943.	2.5	8
91	Melatonin as a proteasome inhibitor. Is there any clinical evidence?. Life Sciences, 2014, 115, 8-14.	2.0	55
92	Î±â€Keto Phenylamides as P1â€²â€Extended Proteasome Inhibitors. ChemMedChem, 2014, 9, 2557-2564.	1.6	12
93	Regulation of PSMB5 Protein and Î² Subunits of Mammalian Proteasome by Constitutively Activated Signal Transducer and Activator of Transcription 3 (STAT3). Journal of Biological Chemistry, 2014, 289, 12612-12622.	1.6	59
94	Adverse Events to Nontargeted and Targeted Chemotherapeutic Agents. Immunology and Allergy Clinics of North America, 2014, 34, 565-596.	0.7	30

#	Article	IF	Citations
96	Rapid Proteasomal Degradation of Posttranscriptional Regulators of the TIS11/Tristetraprolin Family Is Induced by an Intrinsically Unstructured Region Independently of Ubiquitination. Molecular and Cellular Biology, 2014, 34, 4315-4328.	1.1	31
97	Targeting the Ubiquitin-Proteasome System in Heart Disease: The Basis for New Therapeutic Strategies. Antioxidants and Redox Signaling, 2014, 21, 2322-2343.	2.5	55
98	Enzyme Inhibition by Hydroamination: Design and Mechanism of a Hybrid Carmaphycin-Syringolin Enone Proteasome Inhibitor. Chemistry and Biology, 2014, 21, 782-791.	6.2	27
99	MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-Î¹B. Molecular and Cellular Biochemistry, 2014, 395, 253-263.	1.4	13
100	Subunit specific inhibitors of proteasomes and their potential for immunomodulation. Current Opinion in Chemical Biology, 2014, 23, 16-22.	2.8	56
101	Identification of Potent and Selective Non-covalent Inhibitors of the Plasmodium falciparum Proteasome. Journal of the American Chemical Society, 2014, 136, 13562-13565.	6.6	46
102	A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2014, 61, 1754-1760.	0.8	44
103	Structure-Based Design of Î²1i or Î²5i Specific Inhibitors of Human Immunoproteasomes. Journal of Medicinal Chemistry, 2014, 57, 6197-6209.	2.9	89
104	Exploring dual electrophiles in peptide-based proteasome inhibitors: carbonyls and epoxides. Organic and Biomolecular Chemistry, 2014, 12, 5710-5718.	1.5	8
105	Assessing Subunit Dependency of the Plasmodium Proteasome Using Small Molecule Inhibitors and Active Site Probes. ACS Chemical Biology, 2014, 9, 1869-1876.	1.6	46
106	Ubiquitin-proteasome system and hereditary cardiomyopathies. Journal of Molecular and Cellular Cardiology, 2014, 71, 25-31.	0.9	64
107	Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity. Analytical Biochemistry, 2014, 451, 1-3.	1.1	3
108	Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome. ACS Medicinal Chemistry Letters, 2014, 5, 405-410.	1.3	42
109	Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy. Journal of Controlled Release, 2014, 188, 67-77.	4.8	67
110	Negative feedback regulation of NF-Î¹B-inducing kinase is proteasome-dependent but does not require cellular inhibitors of apoptosis. Biochemical and Biophysical Research Communications, 2014, 450, 341-346.	1.0	7
111	The role of bacterial phytotoxins in inhibiting the eukaryotic proteasome. Trends in Microbiology, 2014, 22, 28-35.	3.5	20
114	Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma. Scientific Reports, 2015, 5, 16991.	1.6	44
115	Proteasome inhibitor carfilzomib complements ibrutinibâ€™s action in chronic lymphocytic leukemia. Blood, 2015, 125, 407-410.	0.6	20

#	Article	IF	Citations
116	Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. Blood, 2015, 125, 410-412.	0.6	42
117	Gene expression profiling of CD133-positive cells in coronary artery disease. Molecular Medicine Reports, 2015, 12, 7512-7516.	1.1	3
119	A chemicalâ€“genetic interaction map of small molecules using highâ€throughput imaging in cancer cells. Molecular Systems Biology, 2015, 11, 846.	3.2	79
120	Development of two novel high-throughput assays to quantify ubiquitylated proteins in cell lysates: application to screening of new anti-malarials. Malaria Journal, 2015, 14, 200.	0.8	13
122	Kaposi's sarcoma-associated herpesvirus. Current Opinion in Infectious Diseases, 2015, 28, 611-624.	1.3	16
123	Identification of a Î²1/Î²2â€Specific Sulfonamide Proteasome Ligand by Crystallographic Screening. Angewandte Chemie - International Edition, 2015, 54, 11275-11278.	7.2	12
124	A Systematic Review on Antitumor Agents with 1, 3, 5-triazines. , 2015, 5, .		27
125	Scopadulciol, Isolated from Scoparia dulcis, Induces Î²-Catenin Degradation and Overcomes Tumor Necrosis Factor-Related Apoptosis Ligand Resistance in AGS Human Gastric Adenocarcinoma Cells. Journal of Natural Products, 2015, 78, 864-872.	1.5	21
126	Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discovery Today, 2015, 20, 1061-1073.	3.2	400
127	Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activityâ€Based Probes. ChemBioChem, 2015, 16, 284-292.	1.3	4
128	The Ubiquitin-Proteasome System (UPS) as a Cancer Drug Target: Emerging Mechanisms and Therapeutics. , 2015, , 225-264.		10
129	Misfolded Proteins: From Little Villains to Little Helpers in the Fight Against Cancer. Frontiers in Oncology, 2015, 5, 47.	1.3	29
130	Therapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway. Journal of Clinical Oncology, 2015, 33, 782-785.	0.8	15
131	Optimising methods for the preservation, capture and identification of ubiquitin chains and ubiquitylated proteins by immunoblotting. Biochemical and Biophysical Research Communications, 2015, 466, 1-14.	1.0	107
132	Cryo-EM reveals the conformation of a substrate analogue in the human 20S proteasome core. Nature Communications, 2015, 6, 7573.	5.8	40
133	Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resistance Updates, 2015, 18, 18-35.	6.5	153
134	DOCKTITEâ€”A Highly Versatile Step-by-Step Workflow for Covalent Docking and Virtual Screening in the Molecular Operating Environment. Journal of Chemical Information and Modeling, 2015, 55, 398-406.	2.5	142
135	Crystal structure ofN-{N-[N-acetyl-(S)-leucyl]-(S)-leucyl}norleucinal (ALLN), an inhibitor of proteasome. Acta Crystallographica Section E: Crystallographic Communications, 2015, 71, 254-257.	0.2	2

#	Article	IF	Citations
136	Identification of Novel Proteasome Inhibitors from an Enaminone Library. Chemical Biology and Drug Design, 2015, 86, 322-332.	1.5	5
137	A Quantitative Method to Monitor the Efficacy of Inhibitors Against the Chymotrypsin-Like Activity of the Proteasome in Tobacco Leaf Protoplasts. Plant Molecular Biology Reporter, 2015, 33, 829-840.	1.0	0
138	Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914. Structure, 2015, 23, 407-417.	1.6	55
139	Biological targets and mechanisms of action of natural products from marine cyanobacteria. Natural Product Reports, 2015, 32, 478-503.	5.2	133
140	Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular and Cellular Oncology, 2015, 2, e974463.	0.3	18
141	Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemotherapy and Pharmacology, 2015, 75, 281-291.	1.1	22
142	Cystargolides, 20S Proteasome Inhibitors Isolated from Kitasatospora cystarginea. Journal of Natural Products, 2015, 78, 822-826.	1.5	22
143	Other Nonbiological Approaches to Targeted Cancer Chemotherapy. , 2015, , 493-560.		1
144	Protease inhibition by Heterodera glycines cyst content: evidence for effects on the Meloidogyne incognita proteasome. Nematology, 2015, 17, 91-102.	0.2	3
145	Casein Kinase 1Î´ Is an APC/CCdh1 Substrate that Regulates Cerebellar Granule Cell Neurogenesis. Cell Reports, 2015, 11, 249-260.	2.9	30
146	Highly specific ubiquitin-competing molecules effectively promote frataxin accumulation and partially rescue the aconitase defect in Friedreich ataxia cells. Neurobiology of Disease, 2015, 75, 91-99.	2.1	32
147	Np9, a cellular protein of retroviral ancestry restricted to human, chimpanzee and gorilla, binds and regulates ubiquitin ligase MDM2. Cell Cycle, 2015, 14, 2619-2633.	1.3	16
148	NEDDylation Is Essential for Kaposiâ€™s Sarcoma-Associated Herpesvirus Latency and Lytic Reactivation and Represents a Novel Anti-KSHV Target. PLoS Pathogens, 2015, 11, e1004771.	2.1	43
149	Use of Proteasome Inhibitors. Current Protocols in Immunology, 2015, 109, 9.10.1-9.10.8.	3.6	7
150	Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Research and Therapy, 2015, 17, 17.	1.6	101
151	Multiplexed metagenome mining using short DNA sequence tags facilitates targeted discovery of epoxyketone proteasome inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4221-4226.	3.3	104
152	Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 31, 1-8.	2.5	3
153	Peptide Code-on-a-Microplate for Protease Activity Analysis via MALDI-TOF Mass Spectrometric Quantitation. Analytical Chemistry, 2015, 87, 4409-4414.	3.2	32

#	Article	IF	Citations
154	Structureâ€“activity relationship study of syringolin A as a potential anticancer agent. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4872-4877.	1.0	9
155	Discovery of new $${varvec{Mycobacterium~tuberculosis}}$$ M y c o b a c t e r i u m t u b e r c u l o s i s proteasome inhibitors using a knowledge-based computational screening approach. Molecular Diversity, 2015, 19, 1003-1019.	2.1	11
156	Disease-proportional proteasomal degradation of missense dystrophins. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12414-12419.	3.3	21
157	Regulation of Proteasomal Degradation by Modulating Proteasomal Initiation Regions. ACS Chemical Biology, 2015, 10, 2537-2543.	1.6	13
158	Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines. Bioorganic and Medicinal Chemistry, 2015, 23, 6218-6222.	1.4	8
159	Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria. MBio, 2015, 6, e00253-15.	1.8	69
160	VR23: A Quinolineâ€“Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin Eâ€“Mediated Centrosome Amplification. Cancer Research, 2015, 75, 4164-4175.	0.4	24
161	Regioselective Synthesis of Vinyl Halides, Vinyl Sulfones, and Alkynes: A Tandem Intermolecular Nucleophilic and Electrophilic Vinylation of Tosylhydrazones. Organic Letters, 2015, 17, 18-21.	2.4	75
162	Bisbenzimidazole derivatives as potent inhibitors of the trypsin-like sites of the immunoproteasome core particle. Biochimie, 2015, 108, 94-100.	1.3	7
163	Stress Response Pathways in Cancer. , 2015, , .		3
164	Natural Product Inhibitors of Ubiquitin Conjugation and Deconjugation. Studies in Natural Products Chemistry, 2016, , 207-242.	0.8	3
165	Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview. Molecules, 2016, 21, 927.	1.7	20
166	The cryoâ€‹<scp>EM</scp> structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria. FEBS Journal, 2016, 283, 4238-4243.	2.2	25
167	Incorporation of the Constrained Peptidomimetic, 5â€‹Methylpyridinâ€‹2â€‹one into Peptide Vinyl Sulfones and Peptide Epoxy Ketones is Detrimental for Proteasome Inhibition. European Journal of Organic Chemistry, 2016, 2016, 1132-1144.	1.2	2
169	Search for Inhibitors of the Ubiquitinâ€“Proteasome System from Natural Sources for Cancer Therapy. Chemical and Pharmaceutical Bulletin, 2016, 64, 112-118.	0.6	20
170	Peptide codes for multiple protease activity assay via highâ€‹resolution mass spectrometric quantitation. Rapid Communications in Mass Spectrometry, 2016, 30, 196-201.	0.7	6
171	Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study. Scientific Reports, 2016, 6, 33444.	1.6	34
172	Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening. European Journal of Medicinal Chemistry, 2016, 121, 578-591.	2.6	21

#	Article	IF	Citations
173	Proteasome inhibition by new dual warhead containing peptido vinyl sulfonyl fluorides. Bioorganic and Medicinal Chemistry, 2016, 24, 3429-3435.	1.4	39
174	The Proteasome Stress Regulon Is Controlled by a Pair of NAC Transcription Factors in Arabidopsis. Plant Cell, 2016, 28, 1279-1296.	3.1	72
175	Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer. Bioinformatics, 2016, 32, 1373-1379.	1.8	11
176	Enantiomeric pair of copper(II) polypyridyl-alanine complexes: Effect of chirality on their interaction with biomolecules. Journal of Inorganic Biochemistry, 2016, 160, 1-11.	1.5	13
177	A small molecule mitigates hearing loss in a mouse model of Usher syndrome III. Nature Chemical Biology, 2016, 12, 444-451.	3.9	43
178	Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways. Molecular Aspects of Medicine, 2016, 50, 41-55.	2.7	168
179	Neue Ziele fÃ¼r die Photopharmakologie. Angewandte Chemie, 2016, 128, 11140-11163.	1.6	105
180	Design, Synthesis and Biological Evaluation of a Structurally Simplified Syringolin A Analogues. Chemical and Pharmaceutical Bulletin, 2016, 64, 811-816.	0.6	3
181	Human 20S proteasome activity towards fluorogenic peptides of various chain lengths. Biological Chemistry, 2016, 397, 921-926.	1.2	15
182	New antibiotics from Natureâ€™s chemical inventory. Bioorganic and Medicinal Chemistry, 2016, 24, 6227-6252.	1.4	62
183	Emerging Targets in Photopharmacology. Angewandte Chemie - International Edition, 2016, 55, 10978-10999.	7.2	504
184	Dietary apigenin potentiates the inhibitory effect of interferon-Î± on cancer cell viability through inhibition of 26S proteasome-mediated interferon receptor degradation. Food and Nutrition Research, 2016, 60, 31288.	1.2	11
185	Regulation of pluripotency and differentiation by deubiquitinating enzymes. Cell Death and Differentiation, 2016, 23, 1257-1264.	5.0	59
186	Structural characterization, ROS-inductive and proteasome inhibitory properties of ternary and binary copper(II) complexes of N2- and N2O2-ligands. Inorganica Chimica Acta, 2016, 450, 202-210.	1.2	15
188	Resistance Gene-Guided Genome Mining: Serial Promoter Exchanges in Aspergillus nidulans Reveal the Biosynthetic Pathway for Fellutamide B, a Proteasome Inhibitor. ACS Chemical Biology, 2016, 11, 2275-2284.	1.6	105
189	Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome. ACS Medicinal Chemistry Letters, 2016, 7, 250-255.	1.3	10
190	Structure-Driven Developments of 26S Proteasome Inhibitors. Annual Review of Pharmacology and Toxicology, 2016, 56, 191-209.	4.2	23
191	Hydrated and anhydrous forms of copper(II) complex of 3-methylpicolinic acid, and spectroscopic studies of their ROS-inducing and proteasome inhibition. Journal of Molecular Structure, 2016, 1106, 234-241.	1.8	10

#	Article	IF	Citations
192	An approach to â€œescape from flatlandâ€• chemo-enzymatic synthesis and biological profiling of a library of bridged bicyclic compounds. Organic and Biomolecular Chemistry, 2016, 14, 3821-3837.	1.5	9
193	Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors. Progress in Medicinal Chemistry, 2016, 55, 149-192.	4.1	65
194	The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression. Journal of Biological Chemistry, 2016, 291, 8773-8783.	1.6	50
195	Structure- and function-based design of Plasmodium-selective proteasome inhibitors. Nature, 2016, 530, 233-236.	13.7	208
196	Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. Leukemia, 2016, 30, 1094-1102.	3.3	64
197	Culture-independent discovery of natural products from soil metagenomes. Journal of Industrial Microbiology and Biotechnology, 2016, 43, 129-141.	1.4	109
198	The therapeutic potential of microbial proteasome inhibitors. International Immunopharmacology, 2016, 37, 23-30.	1.7	10
199	Targeting proteasomes in infectious organisms to combat disease. FEBS Journal, 2017, 284, 1503-1517.	2.2	40
200	Inhibition of the Proteasome Î²2 Site Sensitizes Triple-Negative Breast Cancer Cells to Î²5 Inhibitors and Suppresses Nrf1 Activation. Cell Chemical Biology, 2017, 24, 218-230.	2.5	83
201	Mechanistic insights into the impact of Cold Atmospheric Pressure Plasma on human epithelial cell lines. Scientific Reports, 2017, 7, 41163.	1.6	62
202	Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	25
203	Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. Journal of Antibiotics, 2017, 70, 542-550.	1.0	8
204	Discovery of an Inhibitor of the Proteasome Subunit Rpn11. Journal of Medicinal Chemistry, 2017, 60, 1343-1361.	2.9	61
205	Selective Autophagy of BES1 Mediated by DSK2 Balances Plant Growth and Survival. Developmental Cell, 2017, 41, 33-46.e7.	3.1	262
206	Decarboxylative borylation. Science, 2017, 356, .	6.0	312
207	Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia. Neurobiology of Disease, 2017, 103, 113-122.	2.1	7
208	Synthesis and antiproteasomal activity of novel O -benzyl salicylamide-based inhibitors built from leucine and phenylalanine. European Journal of Medicinal Chemistry, 2017, 135, 142-158.	2.6	6
209	Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome. ACS Infectious Diseases, 2017, 3, 176-181.	1.8	19

#	Article	IF	Citations
210	Mutual regulation between Polo-like kinase 3 and SIAH2 E3 ubiquitin ligase defines a regulatory network that fine-tunes the cellular response to hypoxia and nickel. Journal of Biological Chemistry, 2017, 292, 11431-11444.	1.6	15
211	New comprehensive studies of a gold(III) Dithiocarbamate complex with proven anticancer properties: Aqueous dissolution with cyclodextrins, pharmacokinetics and upstream inhibition of the ubiquitin-proteasome pathway. European Journal of Medicinal Chemistry, 2017, 138, 115-127.	2.6	22
212	Privileged Electrophile Sensors: A Resource for Covalent Drug Development. Cell Chemical Biology, 2017, 24, 787-800.	2.5	63
213	Specific targeting of the deubiquitinase and E3 ligase families with engineered ubiquitin variants. Bioengineering and Translational Medicine, 2017, 2, 31-42.	3.9	13
214	High-resolution cryo-EM proteasome structures in drug development. Acta Crystallographica Section D: Structural Biology, 2017, 73, 522-533.	1.1	10
215	Azobenzene-containing photoswitchable proteasome inhibitors with selective activity and cellular toxicity. Bioorganic and Medicinal Chemistry, 2017, 25, 5050-5054.	1.4	33
216	A mammalian nervous-system-specific plasma membrane proteasome complex that modulates neuronal function. Nature Structural and Molecular Biology, 2017, 24, 419-430.	3.6	109
217	3q26â€29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes. FEBS Journal, 2017, 284, 2705-2731.	2.2	16
218	Markovnikovâ€Selective Radical Addition of Sâ€Nucleophiles to Terminal Alkynes through a Photoredox Process. Angewandte Chemie, 2017, 129, 610-614.	1.6	22
219	Markovnikovâ€Selective Radical Addition of Sâ€Nucleophiles to Terminal Alkynes through a Photoredox Process. Angewandte Chemie - International Edition, 2017, 56, 595-599.	7.2	118
220	The proteasome of the differently-diverged eukaryote Giardia lamblia and its role in remodeling of the microtubule-based cytoskeleton. Critical Reviews in Microbiology, 2017, 43, 481-492.	2.7	3
221	Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents. Metallomics, 2017, 9, 1439-1446.	1.0	43
222	Adapting Secretory Proteostasis and Function Through the Unfolded Protein Response. Current Topics in Microbiology and Immunology, 2017, 414, 1-25.	0.7	19
223	Oxidative damage and impairment of protein quality control systems in keratinocytes exposed to a volatile organic compounds cocktail. Scientific Reports, 2017, 7, 10707.	1.6	19
224	Potential peptidic proteasome inhibitors by incorporation of an electrophilic trap based on amino acid derived Î±-substituted sulfonyl fluorides. Bioorganic and Medicinal Chemistry, 2017, 25, 5055-5063.	1.4	16
225	Crystal structure of a low molecular weight activator Blm-pep with yeast 20S proteasome â€“ insights into the enzyme activation mechanism. Scientific Reports, 2017, 7, 6177.	1.6	23
226	The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target. ACS Central Science, 2017, 3, 830-838.	5.3	103
227	Impact of the structures of macrocyclic Michael acceptors on covalent proteasome inhibition. Chemical Science, 2017, 8, 6959-6963.	3.7	5

#	Article	IF	Citations
228	Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome Î²1 and Î²5 subunits. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5172-5178.	1.0	2
229	(Immuno)proteasomes as therapeutic target in acute leukemia. Cancer and Metastasis Reviews, 2017, 36, 599-615.	2.7	29
230	Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity. Journal of Medicinal Chemistry, 2017, 60, 6721-6732.	2.9	70
231	<scp>MG</scp>132â€induced progerin clearance is mediated by autophagy activation and splicing regulation. EMBO Molecular Medicine, 2017, 9, 1294-1313.	3.3	101
232	Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 865-877.	2.5	10
233	Urea-containing peptide boronic acids as potent proteasome inhibitors. European Journal of Medicinal Chemistry, 2017, 125, 925-939.	2.6	23
234	Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of largeâ€scale and targeted quantitative proteomics. Proteomics, 2017, 17, 1600089.	1.3	11
235	Ternary and binary copper(II) complexes: synthesis, characterization, ROS-inductive, proteasome inhibitory, and anticancer properties. Journal of Coordination Chemistry, 2017, 70, 223-241.	0.8	21
236	Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. Hematological Oncology, 2017, 35, 408-419.	0.8	10
237	Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis. Scientific Reports, 2017, 7, 17626.	1.6	7
238	Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 729.	1.8	25
239	MLL-Rearranged Leukemiasâ€"An Update on Science and Clinical Approaches. Frontiers in Pediatrics, 2017, 5, 4.	0.9	292
240	Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice. Endocrinology, 2017, 158, 3097-3108.	1.4	10
241	Inhibition of Candida species via Proteosome Inhibitor MG-262 (ZL3B). Archives of Clinical Microbiology, 2017, 08, .	0.2	0
242	The Effect of Low-Dose Proteasome Inhibition on Pre-Existing Atherosclerosis in LDL Receptor-Deficient Mice. International Journal of Molecular Sciences, 2017, 18, 781.	1.8	10
243	Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide. Investigational New Drugs, 2018, 36, 797-809.	1.2	6
244	Guiding Mitotic Progression by Crosstalk between Post-translational Modifications. Trends in Biochemical Sciences, 2018, 43, 251-268.	3.7	43
245	The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis. Translational Research, 2018, 198, 17-28.	2.2	10

#	Article	IF	Citations
246	Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery. ACS Infectious Diseases, 2018, 4, 301-314.	1.8	60
247	Vinylboronic Acids as Efficient Bioorthogonal Reactants for Tetrazine Labeling in Living Cells. Bioconjugate Chemistry, 2018, 29, 982-986.	1.8	18
248	Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL-1Î² production. Cell Death and Disease, 2018, 9, 162.	2.7	10
249	Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death. European Journal of Medicinal Chemistry, 2018, 146, 636-650.	2.6	9
250	Visible-light-induced multicomponent cascade cycloaddition involving N-propargyl aromatic amines, diaryliodonium salts and sulfur dioxide: rapid access to 3-arylsulfonylquinolines. Chemical Communications, 2018, 54, 1335-1338.	2.2	84
251	Next-generation proteasome inhibitors for cancer therapy. Translational Research, 2018, 198, 1-16.	2.2	99
252	Photo-Driven Synthesis of C6-Polyfunctionalized Phenanthridines from Three-Component Reactions of Isocyanides, Alkynes, and Sulfinic Acids by Electron Donorâ€“Acceptor Complex. Organic Letters, 2018, 20, 1735-1739.	2.4	79
253	Transition-metal-free, visible-light-induced oxidative cross-coupling for constructing Î²-acetylamino acrylosulfones from sodium sulfinates and enamides. Organic Chemistry Frontiers, 2018, 5, 92-97.	2.3	56
254	Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. , 2018, 182, 176-192.		76
255	Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemotherapy and Pharmacology, 2018, 81, 227-243.	1.1	113
256	Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?. Journal of Medicinal Chemistry, 2018, 61, 444-452.	2.9	334
257	Targeting the Ubiquitin Proteasome System in Cancer. , 2018, , .		3
258	Thiasyrbactins Induce Cell Death via Proteasome Inhibition in Multiple Myeloma Cells. Anticancer Research, 2018, 38, 5607-5613.	0.5	2
259	Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome. Frontiers in Chemistry, 2018, 6, 392.	1.8	5
260	Modulation of Protein Quality Control and Proteasome to Autophagy Switch in Immortalized Myoblasts from Duchenne Muscular Dystrophy Patients. International Journal of Molecular Sciences, 2018, 19, 178.	1.8	9
261	Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome. Journal of Medicinal Chemistry, 2018, 61, 10053-10066.	2.9	54
262	Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-m Journal of Medicinal Chemistry, 2018, 61, 11127-11143.	2.9	70
263	Atom Transfer Radical Addition to Alkynes and Enynes: A Versatile Gold/Photoredox Approach to Thio-Functionalized Vinylsulfones. ACS Catalysis, 2018, 8, 8237-8243.	5.5	106

#	Article	IF	Citations
264	A mild light-induced cleavage of the Sâ€“O bond of aryl sulfonate esters enables efficient sulfonylation of vinylarenes. Chemical Science, 2018, 9, 7193-7197.	3.7	31
265	Small Molecules in Hematology. Recent Results in Cancer Research, 2018, , .	1.8	6
266	Carfilzomib. Recent Results in Cancer Research, 2018, 212, 265-283.	1.8	2
267	Preâ€clinical evaluation of proteasome inhibitors for canine and human osteosarcoma. Veterinary and Comparative Oncology, 2018, 16, 544-553.	0.8	14
268	Design, synthesis, and evaluation of cystargolide-based Î²-lactones as potent proteasome inhibitors. European Journal of Medicinal Chemistry, 2018, 157, 962-977.	2.6	9
269	Redox Signaling by Reactive Electrophiles and Oxidants. Chemical Reviews, 2018, 118, 8798-8888.	23.0	232
270	Ethenesulfonyl fluoride derivatives as telomerase inhibitors: structure-based design, SAR, and anticancer evaluation in vitro. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1266-1270.	2.5	19
271	Validation of Babesia proteasome as a drug target. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 394-402.	1.4	13
272	Proteasomeâ€mediated proteostasis: Novel medicinal and pharmacological strategies for diseases. Medicinal Research Reviews, 2018, 38, 1916-1973.	5.0	29
273	Natural products from thioester reductase containing biosynthetic pathways. Natural Product Reports, 2018, 35, 847-878.	5.2	60
274	Proteasome Activation to Combat Proteotoxicity. Molecules, 2019, 24, 2841.	1.7	29
275	Novel Copper Complexes That Inhibit the Proteasome and Trigger Apoptosis in Triple-Negative Breast Cancer Cells. ACS Medicinal Chemistry Letters, 2019, 10, 1328-1335.	1.3	24
276	Visualizing Proteasome Activity and Intracellular Localization Using Fluorescent Proteins and Activity-Based Probes. Frontiers in Molecular Biosciences, 2019, 6, 56.	1.6	19
277	Studies of proteasome inhibition and apoptosis induction in tripleâ€negative breast cancer cells by novel amino acidâ€“polypyridineâ€“copper complex. Applied Organometallic Chemistry, 2019, 33, e5120.	1.7	3
278	The Proteasome as a Drug Target in the Metazoan Pathogen, Schistosoma mansoni. ACS Infectious Diseases, 2019, 5, 1802-1812.	1.8	25
279	Conditional deletion of E11/podoplanin in bone protects against load-induced osteoarthritis. BMC Musculoskeletal Disorders, 2019, 20, 344.	0.8	13
280	Preparation and biological evaluation of soluble tetrapeptide epoxyketone proteasome inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 4151-4162.	1.4	4
281	Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. Cell Chemical Biology, 2019, 26, 1486-1500.	2.5	110

#	Article	IF	Citations
282	Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention. Frontiers in Immunology, 2019, 10, 2557.	2.2	20
283	Cellâ€Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome Î²5 Subunit. ChemMedChem, 2019, 14, 2005-2022.	1.6	5
284	The proteasome as a target for protozoan parasites. Expert Opinion on Therapeutic Targets, 2019, 23, 903-914.	1.5	32
285	Chemical Patterns of Proteasome Inhibitors: Lessons Learned from Two Decades of Drug Design. International Journal of Molecular Sciences, 2019, 20, 5326.	1.8	9
286	Another look at phenolic compounds in cancer therapy the effect of polyphenols on ubiquitin-proteasome system. European Journal of Medicinal Chemistry, 2019, 167, 291-311.	2.6	16
287	The AP2/ERF Transcription Factor TINY Modulates Brassinosteroid-Regulated Plant Growth and Drought Responses in Arabidopsis. Plant Cell, 2019, 31, 1788-1806.	3.1	153
288	Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nature Chemical Biology, 2019, 15, 681-689.	3.9	275
289	Inhibiting the immunoproteasome's Î²5i catalytic activity affects human peripheral bloodâ€derived immune cell viability. Pharmacology Research and Perspectives, 2019, 7, e00482.	1.1	5
290	Synthesis and Biological Activity of Peptide Î±-Ketoamide Derivatives as Proteasome Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 1086-1092.	1.3	16
291	Proteasome: a Nanomachinery of Creative Destruction. Biochemistry (Moscow), 2019, 84, 159-192.	0.7	20
292	Argyrin B, a nonâ€competitive inhibitor of the human immunoproteasome exhibiting preference for Î²1i. Chemical Biology and Drug Design, 2019, 94, 1556-1567.	1.5	7
293	Proteasome Levels and Activity in Pregnancies Complicated by Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Thrombocytopenia (HELLP) Syndrome. Hypertension, 2019, 73, 1308-1318.	1.3	12
294	Recent advances in the genome mining ofAspergillussecondary metabolites (covering) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262	3.5	76
295	Keep calm and carry on: mi<scp>RNA</scp> biogenesis under stress. Plant Journal, 2019, 99, 832-843.	2.8	48
296	Proteasomal inhibition attenuates craniofacial malformations in a zebrafish model of Treacher Collins Syndrome. Biochemical Pharmacology, 2019, 163, 362-370.	2.0	16
297	Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes. ChemMedChem, 2019, 14, 842-852.	1.6	18
298	Highlighting the Proteasome: Using Fluorescence to Visualize Proteasome Activity and Distribution. Frontiers in Molecular Biosciences, 2019, 6, 14.	1.6	23
299	H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth. Scientific Reports, 2019, 9, 4089.	1.6	11

#	Article	IF	Citations
300	A Practical Review of Proteasome Pharmacology. Pharmacological Reviews, 2019, 71, 170-197.	7.1	245
301	Smallâ€Molecule Inhibitors of the Proteasome's Regulatory Particle. ChemBioChem, 2019, 20, 1739-1753.	1.3	10
302	Conversion of Isatins to Tryptanthrins, Heterocycles Endowed with a Myriad of Bioactivities. European Journal of Organic Chemistry, 2019, 2019, 5302-5312.	1.2	10
303	Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. Frontiers in Pharmacology, 2019, 10, 1.	1.6	303
304	Proteostasis In The Endoplasmic Reticulum: Road to Cure. Cancers, 2019, 11, 1793.	1.7	21
305	Temperature-dependent synthesis of vinyl sulfones and Î²-hydroxy sulfones from t-butylsulfinamide and alkenes under aerobic conditions. New Journal of Chemistry, 2019, 43, 17941-17945.	1.4	5
306	Targeting Metalloenzymes for Therapeutic Intervention. Chemical Reviews, 2019, 119, 1323-1455.	23.0	181
307	Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. Cell Chemical Biology, 2019, 26, 340-351.e3.	2.5	83
308	Non-peptidic natural products as ubiquitin-proteasome inhibitors. Tetrahedron, 2019, 75, 817-853.	1.0	6
309	Photoredox Alkenylation of Carboxylic Acids and Peptides: Synthesis of Covalent Enzyme Inhibitors. Journal of Organic Chemistry, 2019, 84, 2379-2392.	1.7	24
310	A new reporter cell line for studies with proteasome inhibitors in Trypanosoma brucei. Molecular and Biochemical Parasitology, 2019, 227, 15-18.	0.5	4
311	Structure-Based Design of Inhibitors Selective for Human Proteasome Î²2c or Î²2i Subunits. Journal of Medicinal Chemistry, 2019, 62, 1626-1642.	2.9	23
312	Renal cold storage followed by transplantation impairs proteasome function and mitochondrial protein homeostasis. American Journal of Physiology - Renal Physiology, 2019, 316, F42-F53.	1.3	15
313	Nucleic Acid Detection and Structural Investigations. Methods in Molecular Biology, 2020, , .	0.4	1
314	Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resistance Updates, 2020, 48, 100663.	6.5	180
315	p-TsOH-mediated synthesis of substituted 2,4-diaryl-3-sulfonylquinolines from functionalized 2-aminobenzophenones and aromatic Î²-ketosulfones under microwave irradiation. Organic and Biomolecular Chemistry, 2020, 18, 305-315.	1.5	17
316	Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. Leukemia Research, 2020, 88, 106271.	0.4	10
317	Regulation of NFÎºB Signalling by Ubiquitination: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma?. Cancers, 2020, 12, 2877.	1.7	20

#	Article	IF	Citations
318	Visibleâ€Lightâ€Induced Radical Cascade Cyclizations of 1,7â€Enynes with Sulfinic Acids: Direct Access to Sulfonated Chromanes and Sulfonated Tetrahydroquinolines under Metalâ€Free Conditions. Advanced Synthesis and Catalysis, 2020, 362, 5669-5680.	2.1	26
319	The Plasmodium falciparum proteasome as a drug target. , 2020, , 403-432.		1
320	Proteasome Inhibitor MG132 is Toxic and Inhibits the Proliferation of Rat Neural Stem Cells but Increases BDNF Expression to Protect Neurons. Biomolecules, 2020, 10, 1507.	1.8	9
321	Myofibril assembly and the roles of the ubiquitin proteasome system. Cytoskeleton, 2020, 77, 456-479.	1.0	12
322	Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System. Molecules, 2020, 25, 4454.	1.7	10
323	COLD REGULATED 27 and 28 are targets of CONSTITUTIVELY PHOTOMORPHOGENIC 1 and negatively affect phytochrome B signalling. Plant Journal, 2020, 104, 1038-1053.	2.8	12
324	Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy. Genes and Immunity, 2020, 21, 273-287.	2.2	25
325	Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21588-21597.	3.3	16
326	Proteasome Biology: Chemistry and Bioengineering Insights. Polymers, 2020, 12, 2909.	2.0	2
327	Acireductone dioxygenase 1 (ADI1) is regulated by cellular iron by a mechanism involving the iron chaperone, PCBP1, with PCBP2 acting as a potential co-chaperone. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165844.	1.8	8
328	The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. , 2020, 213, 107579.		62
329	Exploring the Proteolysis Mechanism of the Proteasomes. Journal of Physical Chemistry B, 2020, 124, 5626-5635.	1.2	12
330	Targeting eukaryotic proteases for natural products-based drug development. Natural Product Reports, 2020, 37, 827-860.	5.2	18
331	MG132 Attenuates the Replication of Classical Swine Fever Virus in vitro. Frontiers in Microbiology, 2020, 11, 852.	1.5	9
332	Exploring the proteasome system: A novel concept of proteasome inhibition and regulation. , 2020, 211, 107526.		27
333	Bortezomib for autoimmune hemolytic anemia after intestinal transplantation. Pediatric Transplantation, 2020, 24, e13700.	0.5	8
335	Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease. Molecules, 2020, 25, 671.	1.7	57
336	Competitive Metabolite Profiling of Natural Products Reveals Subunit Specific Inhibitors of the 20S Proteasome. ACS Central Science, 2020, 6, 241-246.	5.3	15

#	Article	IF	Citations
337	Comprehensive comparison of Yarrowia lipolytica and Pichia pastoris for production of Candida antarctica lipase B. Scientific Reports, 2020, 10, 1741.	1.6	28
338	Immunoproteasome Inhibitorâ€“Doxorubicin Conjugates Target Multiple Myeloma Cells and Release Doxorubicin upon Low-Dose Photon Irradiation. Journal of the American Chemical Society, 2020, 142, 7250-7253.	6.6	16
339	Effect of Ferulic Acid, a Phenolic Inducer of Fungal Laccase, on 26S Proteasome Activities In Vitro. International Journal of Molecular Sciences, 2020, 21, 2463.	1.8	9
340	Design and NMR conformational analysis in solution of Î²5i-selective inhibitors of immunoproteasome. Journal of Molecular Structure, 2021, 1230, 129633.	1.8	2
341	Nature of Irreversible Inhibition of Human 20S Proteasome by Salinosporamide A. The Critical Role of Lysâ€“Asp Dyad Revealed from Electrostatic Effects Analysis. ACS Catalysis, 2021, 11, 3575-3589.	5.5	9
343	Amniotic Fluid Proteasome and Immunoproteasome in the Setting of Intra-Amniotic Infection, Inflammation, and Preterm Birth. Reproductive Sciences, 2021, 28, 2562-2573.	1.1	0
344	A Novel, Universally Active C-terminal Protein Degradation Signal Generated by Alternative Splicing. Journal of Molecular Biology, 2021, 433, 166890.	2.0	1
345	Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling. Journal of Controlled Release, 2021, 332, 563-580.	4.8	11
346	Ubiquitinâ€“proteasome system and the role of its inhibitors in cancer therapy. Open Biology, 2021, 11, 200390.	1.5	46
349	Identification of key regulators responsible for dysregulated networks in osteoarthritis by large-scale expression analysis. Journal of Orthopaedic Surgery and Research, 2021, 16, 259.	0.9	8
351	Highly E-Selective Synthesis of Î±-Fluoro-Î²-arylalkenyl Sulfones from gem-Difluoroalkenes with Sodium Sulfinates. Journal of Organic Chemistry, 2021, 86, 6983-6993.	1.7	9
352	Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLLâ€“AF4 fusion protein. Scientific Reports, 2021, 11, 10883.	1.6	20
353	Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. Pharmacological Research, 2021, 167, 105537.	3.1	12
354	A Proteasome Mutation Sensitizes P.Âfalciparum Cam3.II K13^{C580Y} Parasites to DHA and OZ439. ACS Infectious Diseases, 2021, 7, 1923-1931.	1.8	6
355	Marine Streptomyces sp. Isolated From the Brazilian Endemic Tunicate Euherdmania sp. Produces Dihydroeponemycin and Analogs With Potent Antiglioma Activity. Frontiers in Marine Science, 2021, 8, .	1.2	2
356	2-D08 treatment regulates C2C12 myoblast proliferation and differentiation via the Erk1/2 and proteasome signaling pathways. Journal of Muscle Research and Cell Motility, 2021, 42, 193-202.	0.9	3
357	Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells. HemaSphere, 2021, 5, e602.	1.2	5
358	Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (Î²5i). Journal of Medicinal Chemistry, 2021, 64, 10230-10245.	2.9	19

#	Article	IF	Citations
360	Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome. Drug Metabolism and Disposition, 2021, 49, 810-821.	1.7	9
361	Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells. Scientific Reports, 2021, 11, 19051.	1.6	18
362	The ubiquitin-proteasome system in normal hearing and deafness. Hearing Research, 2022, 426, 108366.	0.9	2
363	Pseudopeptides with aldehyde or vinylsulfone warheads: Synthesis and antiproteasomal activity. Bioorganic Chemistry, 2021, 115, 105228.	2.0	1
364	The von Hippelâ€“Lindau Cullin-RING E3 ubiquitin ligase regulates APOBEC3 cytidine deaminases. Translational Research, 2021, 237, 1-15.	2.2	5
365	Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs. Methods in Molecular Biology, 2020, 2063, 207-234.	0.4	8
366	Homogeneous, Bioluminescent Proteasome Assays. Methods in Molecular Biology, 2015, 1219, 95-114.	0.4	4
367	The Proteasome System in Health and Disease. Advances in Experimental Medicine and Biology, 2020, 1233, 55-100.	0.8	19
369	Preclinical Studies on the Molecular Basis of Bortezomib Resistance and Modalities to Overcome Resistance in Hematological Malignancies. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 181-204.	0.1	1
370	Oxidant-directed chemoselective sulfonylation and sulfonyloximation of alkenes via cleaving the Câ€“S bond in TosMIC. Organic Chemistry Frontiers, 2019, 6, 835-840.	2.3	29
371	Natural allosteric modulators and their biological targets: molecular signatures and mechanisms. Natural Product Reports, 2020, 37, 488-514.	5.2	18
372	Identification of ubiquitinated proteins. Materials and Methods, 0, 4, .	0.0	1
373	Fission Yeast 26S Proteasome Mutants Are Multi-Drug Resistant Due to Stabilization of the Pap1 Transcription Factor. PLoS ONE, 2012, 7, e50796.	1.1	12
374	Characterization and Quantification of Intact 26S Proteasome Proteins by Real-Time Measurement of Intrinsic Fluorescence Prior to Top-down Mass Spectrometry. PLoS ONE, 2013, 8, e58157.	1.1	20
375	Blocking Plasmodium falciparum Development via Dual Inhibition of Hemoglobin Degradation and the Ubiquitin Proteasome System by MG132. PLoS ONE, 2013, 8, e73530.	1.1	54
376	Protein Kinase CK2 Inhibition Down Modulates the NF-ÎºB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE, 2013, 8, e75280.	1.1	75
377	Recent Advances Towards the Development of a Potent Antiviral Against the Hepatitis E Virus. Journal of Clinical and Translational Hepatology, 2018, 6, 1-7.	0.7	3
378	A Cycle of Altered Proteasome and Reactive Oxygen Species Production in Renal Proximal Tubular Cells. , 2019, 4, 13-17.		4

#	Article	IF	Citations
379	The 26S proteasome is a multifaceted target for anti-cancer therapies. Oncotarget, 2015, 6, 24733-24749.	0.8	69
380	Emodin potentiates the antiproliferative effect of interferon Î±/Î² by activation of JAK/STAT pathway signaling through inhibition of the 26S proteasome. Oncotarget, 2016, 7, 4664-4679.	0.8	25
381	Gene 33/Mig6 inhibits hexavalent chromium-induced DNA damage and cell transformation in human lung epithelial cells. Oncotarget, 2016, 7, 8916-8930.	0.8	19
382	Therapeutic Applications of Peptides against Zika Virus: A Review. Current Medicinal Chemistry, 2020, 27, 3906-3923.	1.2	8
383	Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System. Current Cancer Drug Targets, 2014, 14, 517-536.	0.8	224
384	Combined Three Dimensional Quantitative Structure Activity Relationships (3D-QSAR) Modeling and Molecular Docking Studies on Naphthoquinone Analogs as Proteasome Inhibitors. Letters in Drug Design and Discovery, 2012, 10, 129-144.	0.4	1
385	Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment. Molecular Medicine Reports, 2019, 19, 5023-5029.	1.1	2
386	Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. ELife, 2015, 4, .	2.8	67
387	Detection and manipulation of live antigen-expressing cells using conditionally stable nanobodies. ELife, 2016, 5, .	2.8	77
388	Immunoproteasome functions explained by divergence in cleavage specificity and regulation. ELife, 2017, 6, .	2.8	66
389	Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound. Cell Death and Disease, 2021, 12, 914.	2.7	3
390	Nostocyclopeptides as New Inhibitors of 20S Proteasome. Biomolecules, 2021, 11, 1483.	1.8	2
391	Protein Degradation in Cardiomyocytes: Target Proteins and Clinical Consequences. , 2016, , 191-222.		1
394	Effect of Metabolite Extract of Streptomyces hygroscopicus subsp. hygroscopicus on Plasmodium falciparum 3D7 in Vitro. Iranian Journal of Parasitology, 0, , .	0.6	1
396	Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells. Oncology Research, 2020, 28, 497-507.	0.6	3
397	Identification of a novel compound that simultaneously impairs the ubiquitin-proteasome system and autophagy. Autophagy, 2022, 18, 1486-1502.	4.3	2
398	A base-controlled switch of SO2 reincorporation in photocatalyzed radical difunctionalization of alkenes. CheM, 2021, 7, 3412-3424.	5.8	36
400	Design, Synthesis and Evaluation of Substituted Aryl-2-Nitrovinyl Derivatives as Small Molecules Proteasome Inhibitors. Iranian Journal of Pharmaceutical Research, 2018, 17, 906-916.	0.3	1

#	Article	IF	Citations
402	Effect of Metabolite Extract of subsp. on 3D7 in Vitro. Iranian Journal of Parasitology, 2019, 14, 444-452.	0.6	3
403	Anticancer chiral and racemic ternary copper(II) complexes: Multiple mechanisms and epigenetic histone methyltransferase enzymes as novel targets. Polyhedron, 2022, 213, 115617.	1.0	3
404	Atomistic Simulations of the Human Proteasome Inhibited by a Covalent Ligand. , 2021, , 47-57.		0
405	Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma. Nature Communications, 2021, 12, 7318.	5.8	18
407	Site-Specific Proteasome Inhibitors. Biomolecules, 2022, 12, 54.	1.8	24
408	Investigation of the influence of chirality and halogen atoms on the anticancer activity of enantiopure palladium(<scp>ii</scp>) complexes derived from chiral amino-alcohol Schiff bases and 2-picolylamine. New Journal of Chemistry, 2022, 46, 6470-6483.	1.4	12
409	Modulation of the Ubiquitin-Proteasome System Restores Plasticity in Hippocampal Pyramidal Neurons of the APP/PS1 Alzheimerâ€™s Disease-Like Mice. Journal of Alzheimer's Disease, 2022, 86, 1611-1616.	1.2	1
410	Discovery of Novel Epoxyketone Peptides as Lipase Inhibitors. Molecules, 2022, 27, 2261.	1.7	4
411	Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance. Molecules, 2022, 27, 2201.	1.7	11
412	Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors. Cells, 2022, 11, 838.	1.8	1
413	Heterorhabditis and Photorhabdus Symbiosis: A Natural Mine of Bioactive Compounds. Frontiers in Microbiology, 2022, 13, 790339.	1.5	3
414	Production of Epoxyketone Peptide-Based Proteasome Inhibitors by Streptomyces sp. BRA-346: Regulation and Biosynthesis. Frontiers in Microbiology, 2022, 13, 786008.	1.5	0
415	Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment. European Journal of Medicinal Chemistry, 2022, 233, 114211.	2.6	2
416	Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors. Cells, 2022, 11, 9.	1.8	15
417	The Functional and Mechanistic Roles of Immunoproteasome Subunits in Cancer. Cells, 2021, 10, 3587.	1.8	13
418	Fungal Secondary Metabolites as Inhibitors of the Ubiquitinâ€“Proteasome System. International Journal of Molecular Sciences, 2021, 22, 13309.	1.8	9
419	Targeting Oxidative Phosphorylation-Proteasome Activity in Extracellular Detached Cells Promotes Anoikis and Inhibits Metastasis. Life, 2022, 12, 42.	1.1	7
427	Atom- and step-economic 1,3-thiosulfonylation of activated allenes with thiosulfonates to access vinyl sulfones/sulfides. Chemical Communications, 2022, 58, 6765-6768.	2.2	11

#	Article	IF	Citations
428	SMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta. Cells, 2022, 11, 1648.	1.8	7
429	Potency of copper(II) complexes towards drug-sensitive and -resistant Plasmodium falciparum: structure-activity relationship, ROS-generation and proteasome inhibition. Journal of Molecular Structure, 2022, , 133588.	1.8	1
431	Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	7
432	Diagnostic and therapeutic potential of protease inhibition. Molecular Aspects of Medicine, 2022, 88, 101144.	2.7	7
433	Therapeutic peptidomimetics for cancer treatment. , 2022, , 473-505.		0
434	Structural Aspects of Organic Compounds as Proteasome Inhibitors Addressed to Several Diseases. Engineering Materials, 2022, , 545-567.	0.3	0
435	Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents. Royal Society Open Science, 2022, 9, .	1.1	3
436	Novel Class of Proteasome Inhibitors: In Silico and In Vitro Evaluation of Diverse Chloro(trifluoromethyl)aziridines. International Journal of Molecular Sciences, 2022, 23, 12363.	1.8	8
437	Nuclear Organization in Response to Stress: A Special Focus on Nucleoli. Results and Problems in Cell Differentiation, 2022, , 469-494.	0.2	2
439	An efficient approach to 3,4-fused Î´-lactone-Î³-lactams bicyclic moieties as anti-Alzheimer agents. Structural Chemistry, 2023, 34, 1577-1589.	1.0	1
441	Investigation of the Compatibility between Warheads and Peptidomimetic Sequences of Protease Inhibitorsâ€"A Comprehensive Reactivity and Selectivity Study. International Journal of Molecular Sciences, 2023, 24, 7226.	1.8	3
444	Protein degradation-based cancer therapy. , 2023, , 637-679.		0